

# Federica Tomao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7055375/publications.pdf>

Version: 2024-02-01

130  
papers

2,874  
citations

159585

30  
h-index

223800

46  
g-index

131  
all docs

131  
docs citations

131  
times ranked

4790  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple-negative breast cancer: new perspectives for targeted therapies. <i>OncoTargets and Therapy</i> , 2015, 8, 177.	2.0	109
2	Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. <i>OncoTargets and Therapy</i> , 2014, 7, 1223.	2.0	105
3	Bevacizumab in ovarian cancer: A critical review of phase III studies. <i>Oncotarget</i> , 2017, 8, 12389-12405.	1.8	100
4	Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. <i>European Radiology</i> , 2018, 28, 4849-4859.	4.5	100
5	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	17.0	93
6	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016, 15, 1327-1336.	4.4	79
7	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 48.	8.6	72
8	Impaired uterine artery flow associated with the presence of ovarian endometrioma: preliminary results of a prospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 1.	3.0	66
9	Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. <i>Journal of Translational Medicine</i> , 2016, 14, 267.	4.4	65
10	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 650-660.	0.8	65
11	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. <i>Cancer Treatment Reviews</i> , 2019, 80, 101909.	7.7	63
12	Angiogenesis and antiangiogenic agents in cervical cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 2237.	2.0	61
13	Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 52.	8.6	56
14	&lt;p&gt;Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches&lt;p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6109-6129.	2.0	54
15	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	2.5	51
16	Special issues in fertility preservation for gynecologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 206-219.	4.4	51
17	Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 7-14.	7.7	51
18	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?. <i>Cancer</i> , 2017, 123, 3450-3459.	4.1	48

#	ARTICLE	IF	CITATIONS
19	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 769280.	2.8	45
20	Triple-negative breast cancer: investigating potential molecular therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 55-75.	3.4	44
21	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1721.	2.4	43
22	MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 99.e1-99.e7.	1.3	40
23	Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. <i>Endocrine-Related Cancer</i> , 2013, 20, R233-R245.	3.1	39
24	Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. <i>Journal of Cancer</i> , 2014, 5, 301-310.	2.5	39
25	Immunologic treatments for precancerous lesions and uterine cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 29.	8.6	39
26	Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 9-20.	2.3	37
27	Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies. <i>Gynecologic Oncology</i> , 2014, 132, 125-129.	1.4	35
28	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 31-49.	4.1	35
29	Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent) Tj ETQq1 1 0.784314 rgBT /Overlock 100 505-513.	1.4	35
30	Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIIB cervical cancer patients after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2011, 37, 364-369.	1.0	34
31	Conization in Early Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1001-1008.	2.5	34
32	Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. <i>Chemotherapy</i> , 2017, 62, 111-120.	1.6	33
33	Immunogenicity of Allo-Vesicle Carrying ERBB2 Tumor Antigen for Dendritic Cell-Based Anti-Tumor Immunotherapy. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 647-658.	2.1	30
34	Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements. <i>World Journal of Surgical Oncology</i> , 2013, 11, 285.	1.9	30
35	Current role and safety profile of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1253-1263.	2.4	29
36	Breast cancer metastatic to the pituitary gland: a case report. <i>World Journal of Surgical Oncology</i> , 2012, 10, 137.	1.9	29

#	ARTICLE	IF	CITATIONS
37	Niraparib in ovarian cancer: results to date and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 579-588.	3.2	29
38	Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1443-1455.	1.8	28
39	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	4.4	27
40	Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 254.	2.4	27
41	A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. <i>Journal of Immunotherapy</i> , 2007, 30, 567-576.	2.4	26
42	Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy. <i>Oncology</i> , 2016, 91, 205-210.	1.9	25
43	Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review. <i>Gynecologic Oncology</i> , 2015, 137, 373-379.	1.4	24
44	Endometriosis and Pregnancy: A Single Institution Experience. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 401.	2.6	24
45	Fertility drugs, reproductive strategies and ovarian cancer risk. <i>Journal of Ovarian Research</i> , 2014, 7, 51.	3.0	23
46	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. <i>Cancers</i> , 2019, 11, 1641.	3.7	22
47	Tumor-derived microvesicles: The metastasomes. <i>Medical Hypotheses</i> , 2013, 80, 75-82.	1.5	21
48	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti- $\alpha$ -Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	4.1	21
49	Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 505-513.	2.5	21
50	Role of chemotherapy in the management of vulvar carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 25-39.	4.4	19
51	Fertility-Sparing Options in Young Women with Cervical Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 5.	3.0	19
52	CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset. <i>Cancers</i> , 2022, 14, 2739.	3.7	19
53	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020, 5, e000827.	4.5	18
54	A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. <i>BMC Cancer</i> , 2006, 6, 137.	2.6	17

#	ARTICLE	IF	CITATIONS
55	Ovarian function, reproduction and strategies for fertility preservation after breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 1-12.	4.4	17
56	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
57	Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?. <i>Journal of Cellular Physiology</i> , 2020, 235, 5050-5058.	4.1	17
58	Fertility preservation in ovarian tumours. <i>Ecancermedalscience</i> , 2018, 12, 885.	1.1	16
59	Fertility preservation in gynaecologic cancers. <i>Ecancermedalscience</i> , 2018, 12, 798.	1.1	16
60	Imaging strategy in recurrent ovarian cancer: a practical review. <i>Abdominal Radiology</i> , 2019, 44, 1091-1102.	2.1	16
61	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	2.4	16
62	Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results. <i>Current Drug Targets</i> , 2014, 15, 1107-1120.	2.1	16
63	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 49.	8.6	15
64	An Update of Laparoscopy in Cervical Cancer Staging: Is It a Useful Procedure?. <i>Oncology</i> , 2013, 85, 160-165.	1.9	15
65	Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 37-53.	4.1	15
66	The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e6.	2.2	15
67	Emerging role of pemetrexed in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1727-1735.	2.4	14
68	Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?. <i>Gynecologic Oncology</i> , 2019, 154, 138-143.	1.4	13
69	Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 105-111.	2.3	13
70	Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review. <i>Oncology</i> , 2020, 98, 195-201.	1.9	13
71	The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site. <i>World Journal of Surgical Oncology</i> , 2008, 6, 116.	1.9	12
72	Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 457.	2.0	12

#	ARTICLE	IF	CITATIONS
73	Noadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
74	Complete remission of cerebral endometriosis with dienogest: a case report. <i>Gynecological Endocrinology</i> , 2018, 34, 837-839.	1.7	12
75	Late Breast Cancer Recurrence to the Uterine Cervix With a Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 113-117.	1.4	11
76	Intraperitoneal Chemotherapy by Ultrasound-Guided Direct Puncture in Recurrent Ovarian Cancer: Feasibility, Compliance, and Complications. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1069-1074.	2.5	11
77	Breast cancer risk after exposure to fertility drugs. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 149-157.	2.4	11
78	Current status of bevacizumab in advanced ovarian cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 889.	2.0	11
79	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. <i>Anticancer Research</i> , 2016, 36, 5109-5116.	1.1	11
80	Risk-reducing Salpingo-oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. <i>Anticancer Research</i> , 2017, 37, 5241-5248.	1.1	11
81	Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. <i>Tumor Biology</i> , 2014, 35, 8415-8424.	1.8	10
82	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). <i>Cancers</i> , 2020, 12, 2841.	3.7	10
83	Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3580-3580.	1.6	9
84	Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13650.	4.1	9
85	Phase II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 687-693.	2.3	8
86	Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View. <i>Journal of Clinical Oncology</i> , 2013, 31, 166-167.	1.6	8
87	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Cancer</i> , 2014, 5, 398-405.	2.5	8
88	The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life. <i>Oncology</i> , 2019, 97, 306-310.	1.9	8
89	Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. <i>Annals of Oncology</i> , 2007, 18, 722-729.	1.2	6
90	A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 161.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Benign schwannoma in supraclavicular region: a false-positive lymph node recurrence of breast cancer suspected by PET scan. Archives of Gynecology and Obstetrics, 2014, 290, 583-586.	1.7	5
92	Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors. Oncology, 2020, 98, 10-15.	1.9	5
93	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. International Journal of Medical Sciences, 2021, 18, 2245-2250.	2.5	5
94	Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. Cancers, 2021, 13, 4061.	3.7	5
95	Hot flushes in women with breast cancer: state of the art and future perspectives. Expert Review of Anticancer Therapy, 2014, 14, 185-198.	2.4	4
96	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. Journal of Cancer, 2016, 7, 516-522.	2.5	4
97	Paclitaxel and Pazopanib in Ovarian Cancer. JAMA Oncology, 2018, 4, 1298.	7.1	4
98	The impact of CO2 laser for treatment of Bartholinâ€™s gland cyst or abscess on female sexual function: a pilot study. Gynecological Endocrinology, 2019, 35, 150-154.	1.7	4
99	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel antiâ€™HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	5.1	4
100	The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. Oncology, 2020, 98, 807-813.	1.9	4
101	Clinical use of fertility agents and risk of breast cancer. Current Opinion in Obstetrics and Gynecology, 2014, 26, 130-137.	2.0	3
102	Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Old and Novel Questions. Journal of Clinical Oncology, 2019, 37, 3168-3169.	1.6	3
103	<p>First-Line Treatment Âwith OlaparibÂfor Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>. Cancer Management and Research, 2020, Volume 12, 5479-5489.	1.9	3
104	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.7	3
105	Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis. Journal of Gynecologic Oncology, 2022, 33, .	2.2	3
106	Gonadotropin-Releasing Hormone Agonists for the Preservation of Ovarian Function During Chemotherapy. Journal of Clinical Oncology, 2012, 30, 3310-3311.	1.6	2
107	Is Removing 9 Lymph Nodes a Correct Cutoff to Define Optimal Lymphadenectomy?: The Open Question of Lymph Node Count. International Journal of Gynecological Cancer, 2014, 24, 1358-1358.	2.5	2
108	Pembrolizumab in Programmed Death Ligand 1â€™Positive Endometrial Cancer. Journal of Clinical Oncology, 2017, 35, 3633-3633.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Paclitaxel and Alisertib in Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 909.	7.1	2
110	Intraperitoneal Chemotherapy: A Strategy for the Treatment of Refractory Ascites in Recurrent Endometrial Cancer Patients – Three Case Reports and Review of the Literature. <i>Oncology</i> , 2020, 98, 98-101.	1.9	2
111	Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 616-617.	10.7	2
112	Uterine irradiation as a determinant of infertility and pregnancy losses in young cancer survivors. <i>Ecancermedalscience</i> , 2020, 14, 1032.	1.1	2
113	Axillary and subcutaneous breast metastases from rhinopharyngeal carcinoma: a case report and literature review. <i>Anticancer Research</i> , 2008, 28, 419-23.	1.1	2
114	Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3670-3670.	1.6	1
115	Quality of Life Effects of Ovarian Suppression in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4188-4188.	1.6	1
116	Progesterone therapy in endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 362-363.	1.3	1
117	Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 667-673.	4.1	1
118	Fertility Preservation and Reproductive Health in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e389-e390.	2.0	1
119	Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 935-936.	1.6	1
120	Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100).. <i>Journal of Clinical Oncology</i> , 2014, 32, e12005-e12005.	1.6	1
121	G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?. <i>Journal of Clinical Oncology</i> , 2014, 32, e20672-e20672.	1.6	1
122	The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, e12000-e12000.	1.6	1
123	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	1.1	1
124	Epistaxis in Weekly Paclitaxel Regimen: Is it Really Related to Schedule?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 77-78.	2.5	0
125	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. <i>Tumori</i> , 2014, 100, e309-e313.	1.1	0
126	Breast Cancer Risk After Ovarian Stimulation for In Vitro Fertilization. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1713.	7.4	0



#	ARTICLE	IF	CITATIONS
127	Secondary cytoreductive surgery: surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease. <i>Giornale Italiano Di Ostetricia E Ginecologia</i> , 2017, 39, 36.	0.1	0
128	Update on fertility-sparing treatment in primary and recurrent endometrial cancer. <i>Giornale Italiano Di Ostetricia E Ginecologia</i> , 2017, 39, 16.	0.1	0
129	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5572-5572.	1.6	0
130	Fertility and reproduction in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 245-246.	2.5	0